CION Ameerpet
Finishing breast cancer treatment is a milestone — and the start of a new chapter called survivorship. Good follow-up keeps you safe without taking over your life. For most women who finish treatment for early breast cancer, surveillance is simpler than you might expect: regular visits with a history and clinical exam, an annual mammogram, support to stay on any hormone (endocrine) therapy, and clear guidance on the red-flag symptoms that should prompt a call. At CION, your follow-up plan is individualised by the same tumour-board-led team that planned your treatment.
Follow-up care (also called surveillance or survivorship care) is the planned series of visits and checks that begins once you finish active treatment for breast cancer. Its goals are simple and reassuring: to catch any sign of the cancer returning at the earliest, most treatable stage; to find and manage the late effects of treatment; to keep you on any ongoing medicine such as endocrine therapy; and to support your physical and emotional recovery as you rebuild your life after treatment.
A common worry is that "no chemo, no radiation" means "no monitoring". The opposite is true — follow-up is how your team keeps watch. But good follow-up is also deliberately light-touch for most women: it relies on a careful history, a clinical breast exam, and an annual mammogram, rather than a barrage of scans. That balance — vigilant but not over-testing — is the heart of modern breast cancer surveillance, and it is what gives most survivors years of healthy, low-stress living.
Most early breast cancers that return show up as a symptom or on the annual mammogram. Regular contact means anything new is checked quickly, while it is most treatable.
Follow-up is also where late effects — bone, heart, arm swelling, menopause symptoms, emotional health — are spotted and managed, not just where recurrence is watched for.
For hormone-positive cancer, staying on endocrine therapy for years lowers recurrence — and follow-up visits are where adherence and side effects are reviewed and supported.
For women who have finished treatment for early breast cancer and have no symptoms, the recommended surveillance is simply a history, a clinical exam, and an annual mammogram. Routine whole-body or PET scans and tumour-marker blood tests are not advised when you are symptom-free — large studies found they do not improve survival, and they add radiation, cost and anxiety. Source: NCCN / ASCO breast cancer follow-up guidance.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
There is no single rigid timetable — your schedule is individualised to your stage, subtype and treatment — but most follow-up plans share the same shape. Visits are more frequent in the first two to three years, when the risk of recurrence is highest, and then gradually spaced out to once a year. After about five years, many women move to annual review, often shared with their family doctor. The schedule below is a typical guide; your CION team will set yours.
Each visit is an appointment, not a procedure — it is mostly conversation and a clinical exam, with imaging done on a yearly cycle rather than at every visit.
Visits are usually every three to six months in the first couple of years. This is when most recurrences would show, so closer contact lets your team catch and act on anything new quickly.
As your risk settles, visits typically space out to every six to twelve months. The clinical exam continues, and the annual mammogram remains the imaging backbone.
Most survivors move to once-a-year review, often shared with their GP. Annual mammography continues for life on the remaining and treated breast tissue.
Aggressive subtypes, node-positive disease or ongoing side effects may mean closer review; very low-risk cancers may be seen less often. Your plan reflects your specific case, not a one-size-fits-all rule.
If you have not been to a follow-up before, it helps to know what actually happens. A surveillance visit is built around three reliable tools: a detailed conversation about how you are feeling, a hands-on clinical examination, and — once a year — a mammogram. Together these find the large majority of recurrences in symptom-free survivors, which is why guidelines build follow-up around them rather than around routine scans.
Your doctor asks about new lumps, bone or back pain, breathlessness, persistent cough, headaches, weight loss or unusual fatigue. Many recurrences are first picked up by a symptom you report — so this conversation is genuinely the most important part of the visit.
A physical exam of both breasts (or the chest wall after mastectomy), the scar, the underarm and neck lymph nodes. It is quick, painless, and lets your team feel for changes between mammograms.
An annual mammogram of the treated and remaining breast tissue is the single recommended imaging test for routine surveillance — usually starting 6–12 months after radiation finishes, then yearly.
A breast MRI is added only for specific situations — for example, a known BRCA mutation, very dense breasts, or an unclear mammogram — not as a routine test for everyone.
Your team checks that you are tolerating any ongoing endocrine therapy, reviews side effects, updates bone and heart monitoring where relevant, and answers your questions. Tests beyond this are ordered only if a symptom or finding calls for them.
This is the part of follow-up that surprises many patients, so it deserves a clear, honest explanation. It can feel as though more scans and more blood tests must mean safer monitoring. For symptom-free survivors of early breast cancer, that is simply not what the evidence shows. Large clinical trials compared intensive surveillance — routine whole-body scans, bone scans, chest imaging and tumour-marker blood tests — against the standard of history, exam and annual mammography. The intensive approach did not help women live longer or better. It did, however, generate more false alarms, more unnecessary procedures, more radiation and more anxiety.
So when your CION oncologist does not order a routine PET scan or a CA 15-3 blood test, it is not cost-cutting — it is following the best evidence and protecting you from harm. Scans and markers absolutely have a place: they are used promptly when a symptom or examination finding suggests a problem. The goal is the right test at the right time, not every test all the time.
Survivorship is a long relationship, and it works best with a team that knows your story and follows the evidence rather than ordering tests to fill silence. CION is a woman-headed, tumour-board-led organisation — the same specialists who planned your treatment guide your follow-up, with transparent costs and unhurried consultations across 35+ centres in Telangana and Andhra Pradesh.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumour-board-reviewed, evidence-based survivorship care across 35+ centres in Telangana & AP. Call 1800-202-8726.
If your breast cancer was hormone-receptor-positive, one of the most powerful parts of your follow-up is not a scan at all — it is a tablet you take every day at home. Endocrine (hormone) therapy — tamoxifen for many premenopausal women, or aromatase inhibitors after menopause — is usually taken for 5 to 10 years and meaningfully reduces the chance of the cancer coming back. The catch is that it only works if you keep taking it, and the benefit builds over years.
Side effects such as joint aches, hot flushes or low mood are common and very manageable — but they are also the main reason women stop early. Follow-up visits are exactly where these should be raised, never silently endured. There is almost always something your team can do, from timing changes and simple remedies to switching the type of therapy. Tell us; do not just stop.
Treatment that saves your life can leave longer-term effects, and a good follow-up plan watches for them too. Most late effects are manageable — and many can be prevented or eased with simple, proactive steps. Knowing what to look out for means you can flag anything early, and your team can build the right checks into your survivorship plan rather than waiting for a problem.
One of the most reassuring things about follow-up is that you are not on your own between appointments. Your team would much rather check something that turns out to be nothing than have you wait and worry. The symptoms below do not mean the cancer is back — most have ordinary explanations — but they are worth a prompt call rather than waiting for your next scheduled visit, because catching a recurrence early keeps the most options open.
Trust your instincts: you know your body. A persistent, new and unexplained symptom that lasts more than a couple of weeks deserves a phone call.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
Follow-up is not only something done to you — it is also a partnership, and your everyday choices genuinely matter. While no diet or workout can guarantee against recurrence, a growing body of evidence links healthy habits with lower recurrence risk, fewer late effects and better quality of life for breast cancer survivors. These are gentle, achievable steps to build into your life after treatment.
Whether you finished treatment with us or elsewhere, CION can build or review a clear, individualised survivorship plan — one that keeps you safe without over-testing. Here is how a follow-up pathway typically works, starting with a free consultation.
A specialist reviews your treatment history and reports, answers your questions, and explains what your follow-up should look like — no rushed visit, no unnecessary tests.
Together we set your visit frequency, your annual mammogram timing, and any selective imaging — individualised to your stage, subtype and treatment, not a generic timetable.
We support you to stay on any endocrine therapy, manage side effects, and build in bone, heart and lymphedema checks where relevant — with up to 50% discounts on diagnostics.
Nutrition, exercise, psycho-oncology and a clear "when to call" plan mean you are supported between visits, with the tumour board ready if anything ever needs a closer look.
Hear from patients treated at CION — their diagnosis, treatment path, and how follow-up keeps them moving forward.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.There is no single rule — your schedule is individualised — but most follow-up plans share the same shape. Visits are usually every 3–6 months for the first two years, when recurrence risk is highest, then every 6–12 months in years three to five, and once a year after that. A mammogram is done annually, usually starting 6–12 months after radiation finishes. Higher-risk cancers or ongoing side effects may mean closer review, while very low-risk cancers may be seen less often. Your CION team sets your schedule based on your stage, subtype and treatment, and will tell you exactly when your next visit and next mammogram are due.
A follow-up visit is mostly conversation and examination, not procedures. Your doctor reviews how you are feeling and asks about any new symptoms — lumps, bone pain, breathlessness, cough, headaches, weight loss or fatigue — because many recurrences are first picked up by something you report. They then do a clinical exam of both breasts (or the chest wall after mastectomy), the scar and the lymph nodes. Once a year, a mammogram is arranged. Your team also checks how you are tolerating any ongoing endocrine therapy and reviews bone or heart health where relevant. Further scans or blood tests are ordered only if a symptom or finding calls for them.
This surprises many patients, so it is worth explaining clearly. Large clinical trials compared intensive surveillance — routine whole-body scans, bone scans and tumour-marker blood tests such as CA 15-3 — against the standard of history, clinical exam and annual mammography in symptom-free survivors. The intensive approach did not help women live longer or better. It did cause more false alarms, more unnecessary procedures, more radiation and more anxiety. So when your CION oncologist does not order these for routine monitoring, it is following the best evidence and protecting you from harm, not cutting costs. Scans and markers are used promptly the moment a symptom or examination finding suggests they are needed.
It depends on what tissue remains. If you had a mastectomy on one side but still have your other breast, that remaining breast needs an annual mammogram, as it carries its own risk. After a double mastectomy, routine mammography of the chest wall is generally not performed, because there is little breast tissue left to image; instead, surveillance relies on a careful history and a clinical exam of the chest wall, scar and lymph nodes, with imaging arranged if any change is found. If you had breast-conserving surgery (lumpectomy), the treated breast continues to need an annual mammogram. Your CION team will tell you exactly which imaging applies to your situation.
For hormone-receptor-positive breast cancer, endocrine therapy such as tamoxifen or an aromatase inhibitor is usually taken for 5 to 10 years, and completing the full course is one of the most reliable ways to reduce recurrence — the benefit builds over years. Side effects like joint aches, hot flushes, vaginal dryness or low mood are common and are the main reason women stop early. Please raise them at follow-up rather than stopping on your own — there is almost always something that helps, from timing changes and simple remedies to switching between tamoxifen and an aromatase inhibitor. Stopping early gives up real, proven protection, so tell your team and let them help you continue comfortably.
Call promptly — rather than waiting for your next visit — if you notice a new lump, thickening or skin or nipple change in either breast, along the mastectomy scar or in the underarm; persistent bone or back pain that does not settle over a couple of weeks, especially if it wakes you at night; unexplained breathlessness or a cough lasting more than a couple of weeks; persistent headaches, particularly with nausea or vision changes; or unexplained weight loss or unusual fatigue. Most of these turn out to have ordinary explanations and do not mean the cancer is back, but checking early keeps the most options open. Trust your instincts — your team would much rather check something that turns out to be nothing.
Follow-up watches for more than recurrence. Bone thinning can follow aromatase inhibitors or treatment-induced menopause, so a bone-density (DEXA) scan, calcium, vitamin D and weight-bearing exercise may be part of your plan. Some chemotherapy and HER2-targeted therapy, and radiation to the left chest, can affect the heart over time, so heart function and cardiovascular risk are monitored where relevant. Arm swelling (lymphedema) after node surgery or radiation needs early attention. Treatment-induced menopause, ongoing fatigue, anxiety and low mood are common and treatable, with psycho-oncology support available. The aim of survivorship care is to look after the whole you — not just to scan for cancer returning.
Yes. CION offers a free first consultation for all cancer patients, including survivors who want to build or review a follow-up plan — whether you were treated with us or elsewhere. It is a full 45-minute consultation: a specialist reviews your treatment history and reports, sets an individualised surveillance schedule and mammogram timing, helps you stay on any endocrine therapy, and builds in bone, heart and lymphedema checks where relevant. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics when imaging is genuinely needed. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.